TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06626919: Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

Sponsor: Kite, A Gilead Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT06626919 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06626919 Rescue Dossier →